Tags

Type your tag names separated by a space and hit enter

Rituximab as an effective therapeutic option in refractory Neuro-Behçet syndrome.
J Neuroimmunol. 2020 Jun 26; 346:577308.JN

Abstract

INTRODUCTION

Behçet's disease (BD) is an inflammatory disease of unknown etiology with periods of relapses and remissions. Neuro-Behçet syndrome (NBS) is one of the main causes of long-term morbidity and mortality, making its prompt recognition and early treatment fundamental to achieving a better outcome. Currently there are no treatment guidelines either for BS or NB, making the management of these patients particularly difficult.

CASE PRESENTATION

We present the case report of a patient with pseudo-tumoral lesion and myelitis refractory to steroids and cyclophosphamide who successfully showed remission after treatment with an anti-CD20 therapy.

CONCLUSION

This is the first report of concomitant pseudo-tumoral lesion and myelitis secondary to BS. We found rituximab treatment to be a safe and effective therapeutic option for NB supported by the radiological and clinical improvement achieved in our patient.

Authors+Show Affiliations

Multiple sclerosis and Demyelinating disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico. Electronic address: christianalan.cg@gmail.com.Multiple sclerosis and Demyelinating disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.Multiple sclerosis and Demyelinating disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.Multiple sclerosis and Demyelinating disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.Multiple sclerosis and Demyelinating disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.Multiple sclerosis and Demyelinating disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico; Head of Neurology Department National Institute of Neurology and Neurosurgery, Mexico City, Mexico.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32619893

Citation

Garcia-Estrada, Christian, et al. "Rituximab as an Effective Therapeutic Option in Refractory Neuro-Behçet Syndrome." Journal of Neuroimmunology, vol. 346, 2020, p. 577308.
Garcia-Estrada C, Casallas-Vanegas A, Zabala-Angeles I, et al. Rituximab as an effective therapeutic option in refractory Neuro-Behçet syndrome. J Neuroimmunol. 2020;346:577308.
Garcia-Estrada, C., Casallas-Vanegas, A., Zabala-Angeles, I., Gomez-Figueroa, E., Rivas-Alonso, V., & Flores-Rivera, J. (2020). Rituximab as an effective therapeutic option in refractory Neuro-Behçet syndrome. Journal of Neuroimmunology, 346, 577308. https://doi.org/10.1016/j.jneuroim.2020.577308
Garcia-Estrada C, et al. Rituximab as an Effective Therapeutic Option in Refractory Neuro-Behçet Syndrome. J Neuroimmunol. 2020 Jun 26;346:577308. PubMed PMID: 32619893.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rituximab as an effective therapeutic option in refractory Neuro-Behçet syndrome. AU - Garcia-Estrada,Christian, AU - Casallas-Vanegas,Adriana, AU - Zabala-Angeles,Indhira, AU - Gomez-Figueroa,Enrique, AU - Rivas-Alonso,Verónica, AU - Flores-Rivera,José, Y1 - 2020/06/26/ PY - 2020/05/10/received PY - 2020/06/23/revised PY - 2020/06/23/accepted PY - 2020/7/4/pubmed PY - 2020/7/4/medline PY - 2020/7/4/entrez KW - Myelitis KW - Neuro-Behçet KW - Pseudotumoral lesion KW - Rituximab SP - 577308 EP - 577308 JF - Journal of neuroimmunology JO - J. Neuroimmunol. VL - 346 N2 - INTRODUCTION: Behçet's disease (BD) is an inflammatory disease of unknown etiology with periods of relapses and remissions. Neuro-Behçet syndrome (NBS) is one of the main causes of long-term morbidity and mortality, making its prompt recognition and early treatment fundamental to achieving a better outcome. Currently there are no treatment guidelines either for BS or NB, making the management of these patients particularly difficult. CASE PRESENTATION: We present the case report of a patient with pseudo-tumoral lesion and myelitis refractory to steroids and cyclophosphamide who successfully showed remission after treatment with an anti-CD20 therapy. CONCLUSION: This is the first report of concomitant pseudo-tumoral lesion and myelitis secondary to BS. We found rituximab treatment to be a safe and effective therapeutic option for NB supported by the radiological and clinical improvement achieved in our patient. SN - 1872-8421 UR - https://www.unboundmedicine.com/medline/citation/32619893/Rituximab_as_an_effective_therapeutic_option_in_refractory_Neuro-Behçet_syndrome L2 - https://linkinghub.elsevier.com/retrieve/pii/S0165-5728(20)30307-6 DB - PRIME DP - Unbound Medicine ER -